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Introduction
Cystic fibrosis (CF) is an autosomal recessive, genetic disease 
that affects a variety of organs.1,2 CF is caused by a mutation of 
chromosome 7 which results in defective control of sodium and 
chloride channels found in the cells that line a variety of organs.1,2 
This results in the production of a thick, sticky mucous that 
accumulates in the lungs and pancreatic ducts, as well as other 
mucous-producing organs.1,2
Management of CF includes nutritional support, pancreatic enzyme 
supplementation, fluidification of mucous and regular, intensive 
physiotherapy.1 During periods of exacerbation, antibiotic therapy is 
needed.1
Medical advances have resulted in increased life expectancy in this 
patient population due to early detection through gene analysis and 
timely and intensive management from diagnosis.1 The majority 
of deaths are caused by respiratory failure as a result of years of 
chronic pulmonary infections.1
Cystic fibrosis is the most common indication for lung transplantation 
in individuals under 50 years of age, accounts for 16.8% of all lung 
transplants in adults, and dramatically improves the survival of 
patients with CF with a 10-year survival rate of 45%.3
Case report
A 24-year-old male with CF was admitted to the intensive care unit 
(ICU) following a lung transplant. He had several of the described 
CF-related complications, namely respiratory failure, pancreatic 
insufficiency, CF-related liver disease and osteoporosis. The lung 
transplant took place on a Friday with admission to the ICU late 
Friday afternoon, and a full nutritional assessment took place on day 
three post-transplant.  
Anthropometry
The patient was admitted to a private institution two months pre-
transplant with a weight of 38 kg (body mass index (BMI) 13.9 kg/m²). 
A percutaneous endoscopic gastrostomy (PEG) was inserted and night 
enteral nutrition (EN) was started. Oral nutritional supplementation 
(ONS) was also initiated. During the eight-week stay at the private 
institution, his weight increased to 43 kg (BMI 15.7 kg/m²). He was 
then transferred to a tertiary hospital following the lung transplant. 
He maintained his weight during his post-transplant hospital stay 
and was discharged with a weight of 43 kg. An ideal body weight 
(IBW) of 63 kg (BMI 23kg/m2) was calculated and used in calculating 
requirements. This is the optimal BMI range for male individuals with 
CF according to the current literature.4 
Biochemistry
On admission to the ICU, the electrolyte profile and renal function 
were normal; haemoglobin, mean corpuscular volume (MCV) and 
mean corpuscular haemoglobin (MCH) were low, indicative of 
a hypochromic, microcytic anaemia (which could not be further 
characterised).4 On day nine post-transplant albumin was low 
(27 g/L), and liver function tests (LFTs) were indicative of a 
cholestatic picture [increased alkaline phosphate (ALP) and gamma 
glutamyl transpeptidase (GGT)]. At discharge, albumin had improved 
(34 g/L) but the cholestatic picture remained (Table I).  
Clinical assessment
The patient had been extubated on day two post-transplant. On the 
day of assessment, day three post-transplant, he was coping well 
on nasal cannula and was apyrexial with stable vitals. He had a 
soft, non-tender abdomen and had passed stools. His blood glucose 
levels were in a range of 7–12.5 mmol/l with a continuous infusion 
of insulin at 2 ml/hr (1 unit of rapid acting insulin/ml). The patient 
required re-intubation on day four, due to desaturation. He was 
extubated again on day six post-surgery and transitioned from face 
mask oxygen to nasal cannula. On the days following transplant, his 
blood glucose levels became poorly controlled with increasing doses 
of insulin required. At discharge on day 16 post-surgery he was 
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coping well on room air and walking without assistance. His blood 
glucose control improved and he was discharged without insulin or 
oral hyperglycaemic therapy. 
Dietary management
The patient’s caloric requirements were calculated using the 
European Society of Clinical Nutrition and Metabolism (ESPEN) 
guidelines of 120–150% and the United States (US) recommendations 
of 110–200% of energy needs for age and gender.4 This provided 
a caloric range of 1 759– 3 196 kcal. Protein requirements were 
calculated based on ESPEN guidelines of 20% of total energy (TE) 
which equated to 88–160 g/day.4 
Pre-operatively
As previously indicated a PEG was inserted for nocturnal feeds prior 
to the lung transplant.  During this period he received the hospital 
full ward diet (FWD) of which he was eating approximately 50% 
(900 kCal, 40 g protein), 2 to 3 ONS (800 – 1 200 kcal, 
40–60 g protein) and 1L semi-elemental feed via PEG overnight 
(1 330 kcal, 67 g protein). This provided in total 3 030 – 3 430 kcal 
TE and 147–167 g protein, within the calculated range. The patient 
was on pancreatic enzyme replacement (PERT) of 25 000 IU at 
meals and 10 000 IU at snacks and on supplementation of vitamin A 
(50 000 IU 3 times/week), vitamin D (50 000 IU once weekly), vitamin 
E (500 IU daily) and vitamin K (10 mg weekly), calcium (1 000 mg 
daily) and zinc (11 mg/day).
Post-operatively
The patient had been extubated on day one post-transplant but by 
day three had only taken in oral fluids and PEG feeds had not been 
restarted. On day three post-transplant night EN was recommenced 
via the PEG. A semi-elemental feed was prescribed that provided 
1 330 kcal and 67 g of protein. The patient was also started on 
the FWD and 2 to 3 ONS (800–1 200 kcal, 40–60g protein). This 
provided in total 2 130–2 530 kCal and 107–127g protein, within 
the calculated range. 
The patient however required reintubation on the afternoon of day 
three post-transplant and therefore was unable to take in orally. On 
day four post-transplant continuous EN of a semi-elemental feed 
was prescribed, which provided 2 660 kcal and 134 g of protein 
(42 kcal/kg IBW TE and 2.1 g/kg IBW protein) as per calculated 
requirements. The patient was extubated successfully on day six 
post-transplant and continued to be fed continuously until day 
10 post-transplant when he began to take in orally. The feeding 
regimen was then changed to continuous night feeds over a 12-
hour period of a semi-elemental feed which provided 1 330 kcal and 
67 g protein, FWD and 2 to 3 ONS (800–1 200 kcal, 40–60g protein). 
He was taking approximately 75% of the FWD and managing his 
ONS well. Oral intake provided approximately 3 330–3 730 kcal TE 
and 152–172 g of protein. PEG feeds were therefore stopped. The 
patient maintained his weight on the FWD and ONS until discharge. 
The patient continued to receive PERT and vitamin A, D, E and K, 
calcium and zinc supplementation (dosages mentioned above) post-
transplant. This regimen was also continued on discharge.
Literature review
Nutritional status, assessment and monitoring of CF patients 
Undernutrition is common in CF due to a number of factors such 
as the underlying genetic mutation, increased caloric requirements, 
increased energy losses, increased essential fatty acid turnover, 
Table I. Relevant biochemistry 
Normal Values Admission Day 1 Day 2 Day 4 Day 6 Day 9 Day 16
Sodium 135–147 mmol/l-¹ 141 145 142 136 140 131 142
Potassium 3.3–5.3 mmol/l-¹ 5.5 4.4 5.0 4.4 5.9 6.6 5.6
Urea 2.6–7.0 mmol/l-¹ 6.7 7.0 5.6 6.4 6.1 5.9 5.5
Creatinine 60–120 µmol.L-¹ 60 65 53 78 69 71 81
Haemoglobin 14.3–18.3 mmol.L-¹ 9.2 10.7 9.6 9.0 7.2 8.2 8.7
MCV 83.1–101.6 fL 80.2 79.1 77.5 76.4 80.8 80.2 82.5
MCH 27.8–34.8 pg 27.1 26.7 27.0 26.5 26.6 27.1 26.7
WBC 4–10 x 10- 10.28 14.78 22.39 24.65 2.71 10.14 10.68
Calcium (corrected) 2.05–2.56 mmol/l-¹ 2.17 2.04 2.06 2.04 2.04
Magnesium 0.65–1.1 mmol/l-¹ 0.99 0.95 1.35 0.97 0.62
Phosphate 0.8–1.4 mmol/l-¹ 2.22 1.38
Albumin 35–52 g/L 27 34
DBil 0–3 umol/L 3 2
ALT 5–40 U/L 58 27
AST 5–40 U/L 41 19
ALP 40–120 U/L 275 294
GGT 0–60 U/L 234 259
WBC: White Blood count; MCV: mean corpuscular value, MCH: mean corpuscular haemoglobin; DBil: conjugated bilirubin; ALT: alanine transaminase; AST: aspartate transaminase; ALP: alkaline phosphate;  
GGT: gamma glutamyl transpeptidase
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a decreased dietary intake and decreased absorption of certain 
nutrients.4 In this regard, an association has been reported between 
poor nutritional status and declining lung function in these patients, 
which leads to increased mortality.4 Alternatively, there is a link 
between good nutritional status and improved lung function.4 
Individuals with CF should be monitored and nutritional status 
assessed on a regular basis (Table II).4 This facilitates the early 
identification of nutritional deficits so that treatment/interventions 
can be implemented.4 In adults, weight, height and calculation of 
BMI should be undertaken at each clinic visit.4,6 A multidisciplinary 
team should assess caloric intake, malabsorption and other factors 
that may influence poor weight gain.4,6 There are a number of tools 
that can be used such as ONS, medications, behavioural therapy, 
nutritional therapies and enteral tube feeding.4,6 
In adults (> 18 years) with CF, a focus on BMI targets is emphasised 
and BMI values are now recommended as the most accurate 
predictor of nutritional risk.4 These targets are above 22 kg/m² 
in females and above 23 kg/m² in males.4,6 It is important to note 
that BMI does not fully define nutritional status in these patients.4 
Increased weight from high fat mass and low lean body mass is 
associated with poor prognosis in CF patients.4,6 Therefore future CF 
guidelines need to encompass the measurement of lean body mass 
in this patient population.4,5,6 Table II summarises the nutritional 
status assessment methods and timing for this patient population. 
Decision for intensified nutritional support
It is recommended that nutritional intervention be based on a full 
review of nutritional status.4 This involves a review of adequacy 
and dosage of PERT and underlying medical conditions that could 
contribute to malnutrition.4 BMI cut-offs are used to determine 
whether progressive and more specialised nutrition intervention is 
necessary (Table III).4
EN should be considered in individuals with a persistently low BMI 
(< 18.5) and/or ongoing weight loss (> 5%), where diet modification 
and/or ONS have failed to improve nutritional status.4 EN can be 
administered as continuous infusions or as bolus feeds.4 They can 
be given over a 24-hour period or as nocturnal feeds.4 Nocturnal 
feeds can be beneficial as these make it easier for patients to eat a 
high calorie diet during the day.4 
There is not enough evidence in the literature to recommend a specific 
type of enteral formula (polymeric, semi-elemental, elemental).4,6 
According to ESPEN guidelines, most individuals tolerate high calorie 
(1.5–2 kcal/ml) polymeric formulas well. In individuals who do not, 
an elemental or semi-elemental formula can be used.4 
There is insufficient evidence regarding the administration of PERT 
with EN.4,6 The most commonly used method is to give PERT at the 
beginning and end of the feed infusion and in the middle of the night 
if necessary.4 Bolus feeds may require more frequent and higher 
doses of PERT.4,6  
Parenteral nutrition is rarely used in CF patients and should only be 
used where enteral feeding is contraindicated.4,6
CF-related complications with nutritional 
consequences
Pancreatic insufficiency
Pancreatic insufficiency (PI) occurs in a large number of CF 
individuals.4 PI is defined as a decrease in digestive enzymes and 
is associated with malabsorption.4 PERT is recommended for all 
patients with PI.4,5 PERT adequacy should be determined clinically by 
monitoring nutritional status, symptoms of malabsorption, excessive 
appetite and poor weight gain or weight loss.4,5 These parameters 
should be monitored every six months in adults with CF.4 Table IV 
shows dosage guidelines for initiation and continuation of PERT. 
Table II. Assessment of nutritional status for adult patients with cystic fibrosis4
Assessment method and timing
Weight 
monitoring
• Measure weight at each clinic visit. 
• Clinic visits at least every three months. 
Nutrition 
monitoring
• Annual nutritional review including blood tests (full blood count, iron status, plasma fat-soluble vitamin levels, plasma or serum 
phospholipid fatty acid patterns, serum liver function and electrolyte measurements).
• Monitor pancreatic enzyme replacement therapy (PERT) and vitamin levels three to six months after initiation or change in dosage.
• Consider the following markers of risk for malnutrition:
 ◦ Measurement of pulmonary function
 ◦ Annual assessment of pancreatic function (by faecal pancreatic elastase-1 determination) in pancreatic-sufficient individuals.  
More frequent tests if nutritional status is poor/not improving.
 ◦ Assessing for PERT need or adequacy of treatment every six months by monitoring nutritional status. Use a 72-hour faecal fat 
measurement and the calculation of the coefficient of fat absorption in patients whose nutritional status is questionable.
Dietary review • A dietary review (which includes questions regarding adherence to advice) should be conducted at least every six months. 
Table III. Consensus guidelines on nutrition intervention in cystic fibrosis4
Nutritional status Intervention Decision point for intensified nutrition support
Adults (> 18 years)
Normal nutritional status Preventative nutritional counselling BMI: 18.5–22 (for females); 18.5–23 (for males), or no weight loss
Impaired nutritional status Diet modification and/or oral nutritional supplements BMI < 18.5, or weight loss of 5% in previous two months 
Persistent undernutrition Enteral tube feeding Persistently low BMI (< 18.5), or  ongoing weight loss of > 5% 
*BMI = Body Mass Index
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Table IV. Pancreatic enzyme replacement therapy (PERT) dosage guidelines3
Age Suggested dosage
Children > 4 years and adults Start at 500 U lipase/kg/meal and 
titrate upwards to a maximum dose of:
-1 000–2 500 U lipase/kg/meal, or
-10 000 U lipase/kg/day, or
-2 000–4 000 U lipase/gram dietary 




Osteoporosis and osteopenia are common in many adolescents 
and adults with CF.4,5 Low bone mineral density is associated with 
decreased ability to work, increased risk of fractures, severe lung 
disease, essential fatty acid (EFA) insufficiency and decreased 
fat mass.4 Poor nutritional status and deficiencies of vitamin D, K 
and calcium are all indicators of nutritional risk.4 CF individuals 
with osteopenia or osteoporosis should be educated on increasing 
their intake of dietary sources of calcium and EFAs. Supplemental 
calcium, vitamin D and vitamin K may also be warranted.4,5 The use 
of bisphosphates can be considered on an individual basis.4 Factors 
such as bone mineral density, history of fractures and transplant 
status should be considered.4 It is also recommended that individuals 
with CF exercise regularly and include weight-bearing exercise as 
this has been shown to improve bone mineral density.4 
CF-related diabetes 
Many individuals with CF develop CF-related diabetes (CFRD) due to 
decline in the endocrine function of the pancreas over time.4 CFRD 
is becoming more prevalent as individuals with CF are living longer 
and the prevalence of CFRD increases with age.4 CFRD negatively 
affects lung function as there is an increase in bacterial colonisation 
of the lungs with increased blood glucose levels.8 It is recommended 
that CF individuals over the age of 10 years are screened for glucose 
tolerance annually.4,5 The American Diabetes Association, Cystic 
Fibrosis Foundation and the Paediatric Endocrine Society advise 
a high calorie diet where carbohydrate intake is individualised 
and regularly monitored to obtain good glycaemic control.4,5 A 
higher protein intake and high fat intake that includes EFAs is 
recommended.4,6 The use of artificial sweeteners should be limited 
as these can prevent adequate caloric intake.8 Education should also 
include advice on insulin therapy and aerobic exercise.8 Insulin is 
recommended as the treatment of choice as there is insufficient 
evidence for the use of oral hypoglycaemic agents in CFRD.4,5
Liver disease
A large number of individuals with CF will develop liver disease 
ranging from mild biliary fibrosis to end-stage cirrhosis.5 Cystic 
fibrosis related liver disease (CFLD) usually presents before 20 years 
of age.5 Some individuals with CFLD develop portal hypertension, 
which can cause variceal bleeding and hepatic failure.4,5 There is 
an association between liver disease and hepatic steatosis in CF 
individuals.4 ESPEN therefore recommends supplementation with 
fat-soluble vitamins and EFAs. Older individuals with CF may develop 
liver failure.4 There is an association between impaired liver function 
and declining lung function.4 All individuals with CF should receive 
routine physical examinations and liver enzyme tests should be 
undertaken on an annual basis.5
Gastrointestinal complications
There are a number of gastrointestinal complications associated 
with CF.5 
Gastroesophageal reflux disease (GORD) affects approximately 30% 
of individuals with CF.5 Care providers should be aware of signs and 
symptoms of GORD and appropriate diagnostic testing and treatment 
should be provided.4,5 
Constipation is frequently experienced by CF individuals.5 Treatment 
usually involves education on adequate diet and hydration and the 
use of stool softeners or laxatives.5 Enemas are not usually needed.5
Fibrosing colonopathy (FC) is a rare complication in CF individuals 
and is usually caused by overuse of PERT.5 It is characterised by 
thickening of the bowel wall and generalised narrowing of the bowel 
lumen.5 The ascending colon is most commonly affected but the 
entire colon can be affected.5 Using the appropriate dosage of PERT, 
not increasing dosages unnecessarily and not exceeding a total 
enzyme dosage of 10000 lipase units/kg/day to prevent FC are the 
only recommendations to prevent FC.5 
CF individuals with small bowel bacterial overgrowth (SBBO) 
experience symptoms such as abdominal pain, nausea, excessive 
flatulence and malabsorption (with adequate PERT).5 Diagnosis 
should be made based on a clinical trial of metronidazole to treat the 
bacterial overgrowth.5 A referral to a gastroenterologist is necessary.5
Energy and protein requirements
CF patients have higher energy needs than the general population.4 
This is due to various factors such as chronic inflammation, impaired 
lung function, malabsorption and the presence of acute respiratory 
exacerbations.4 ESPEN guidelines recommend that adult CF patients 
should receive 120–150% of energy requirements for same-
age healthy populations to maintain BMI targets.4 In comparison, 
US guidelines recommend that CF adult patients should receive 
110–200% of energy requirements for same-age healthy populations 
to maintain BMI targets.4 
Protein needs are estimated to be higher in individuals with CF, 
compared to the general population. Current recommendations are 
that protein should be 20% or more of TE intake.4 Further studies are 
needed to determine more definitive guidelines for protein.4
Essential fatty acids (EFAs)
Humans are unable to synthesise EFAs and therefore they have to be 
obtained via dietary sources.4,6  EFA deficiency is more common in 
CF individuals with pancreatic insufficiency due to the malabsorption 
of fat.4,6 EFA deficiency may present as dermatitis, alopecia and/or 
thrombocytopaenia.6 Low DHA (docosahexaenoic acid) and high 
AA (arachidonic acid) is associated with decreased bone mineral 
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density among children and young adults with CF.4 Consideration 
of EFA deficiency and treatment is recommended by the Cystic 
Fibrosis Foundation in individuals with poor weight gain or weight 
loss.6 A few studies have demonstrated that increased intake of 
EFAs may improve lung function.4,6 Some studies have shown 
that supplementation with omega-3 fatty acids may deliver anti-
inflammatory benefits with few negative side-effects.4,6 At present, 
there is insufficient evidence to make specific recommendations 
regarding dietary supplementation of EFAs.4,6  
Electrolytes, minerals and trace elements
Individuals with CF have increased requirements for certain 
electrolytes, minerals and trace elements compared with non-CF 
individuals.4,6 
Excessive salt loss through sweat can cause decreased levels of 
sodium.4,6 Most adults with CF will obtain adequate sodium from 
a Western diet that includes processed foods.4 However certain 
conditions such as fever, exercise and hot weather can result in 
increased sweat production and depleted levels.4,7 Supplementation 
is recommended in these situations and can be given in the form 
of additional salty foods, sodium chloride capsules or vials.4,7 
Individuals in temperate climates or while exercising may require 
extra sodium supplementation in the form of salted sports drinks.4,7 
Patients with CF often have low levels of calcium.4,7 This is due to a 
combination of decreased intake of dietary sources of calcium and 
a deficiency of vitamin D.4 Gastrointestinal malabsorption, due to 
PI, that is not fully corrected by PERT may also cause decreased 
calcium levels.4 Calcium intake should be assessed annually or more 
often if necessary.4,7  Individuals with suboptimal levels of calcium 
should be counselled on increasing their intake of dietary sources 
of calcium.4 If dietary intake remains low, a calcium supplement is 
recommended.4,7  
Iron deficiency is common in patients with CF with an estimate that 
more than 50% of stable adult CF patients have an iron deficiency.4,7 
There are a number of factors that can contribute to iron deficiency, 
such as chronic infection and inflammation, inadequate dietary 
intake, malabsorption and blood loss. It is recommended that patients 
are only started on iron supplementation if a deficiency persists 
once underlying inflammation and infection have been treated and 
resolved.4,7 Individuals with CF should be routinely monitored for 
anaemia by first obtaining serum iron levels.4 If serum iron levels are 
low it is important to distinguish between iron deficiency anaemia 
(IDA) and anaemia of chronic disease/inflammation (ACD/AI).4 In 
cases of ACD/AI, supplementation is cautioned as iron overload may 
exacerbate the oxidative stress from chronic inflammation in CF.7 
Table V shows how to differentiate between IDA and ACD/AI.4,7
There are a number of studies that have reported altered zinc status 
in CF individuals.4 Zinc plays an important role in both immunity 
and growth.6 Plasma zinc levels are not a sensitive indicator of 
zinc status as it is influenced by a variety of conditions.4 Zinc 
supplementation is recommended in CF individuals at risk of a zinc 
deficiency.4 Factors such as increased number of infections due to 
impaired immune function, eye and skin lesions, hair loss, diarrhoea, 
taste abnormalities, delayed wound healing and anorexia may be 
indicative of a zinc insufficiency.4
Fat-soluble vitamins
Malabsorption due to PI can result in deficiencies in fat-soluble 
vitamins (Table VI).4,7 Some CF individuals who are pancreatic 
sufficient have also been shown to be at risk for fat-soluble vitamin 
deficiencies.4 It is recommended that plasma levels of fat-soluble 
vitamins are measured annually or more often if necessary, in CF 
individuals without proven PI.4 For PI individuals it is recommended 
that plasma levels of fat-soluble vitamins be measured at initiation 
of PERT and vitamin supplementation and three to six months later 
or if there were changes in the supplementation regimen.4 Fat-
soluble vitamin supplements should be taken with a high fat food 
and PERT.4,7
Vitamin A deficiency has been reported in 10–40% of CF individuals.4,7 
Suboptimal vitamin A levels are associated with declining lung 
function, increased exacerbations and worsened clinical status.4,7 
Vitamin A toxicity is an important factor to consider when deciding 
on supplementation.7 Vitamin A supplementation should aim to 
achieve the normal range of serum retinol concentrations for 
healthy individuals.4 Beta-carotene is a precursor to vitamin A and is 
controlled by a negative feedback mechanism and is therefore safer 
to use than retinol (Table VI).4 
Vitamin D has an important role in intestinal calcium absorption 
and a deficiency can result in decreased bone mineral density 
(BMD).4,7 A major source of vitamin D is sunlight, however exposure 
is often limited.4,7 Serum 25-hydroxy vitamin D (25(OH)D) is used 
to monitor vitamin D status.4,7 Supplementation is recommended 
to maintain serum 25(OH)D above 20 ng/mL (50 nmol/L).4 Vitamin 
D3 (cholecalciferol) is recommended over vitamin D2.4 It is 
recommended that serum 25(OH)D is monitored annually, preferably 
at the end of winter.4
Alpha-tocopherol is the major compound of vitamin E.4 Vitamin 
E deficiency can cause a variety of serious side-effects such 
Table V. How to differentiate between different forms of anaemia4
Iron deficiency anaemia (IDA) Anaemia of chronic inflammation Both forms of anaemia 
Serum iron Below normal Below normal Below normal
Serum ferritin Below normal Above normal Varies
Total iron binding capacity Above normal Below or normal Varies
Transferrin saturation (%) Below normal Below normal Below normal
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as neuromuscular degeneration, haemolytic anaemia and both 
retinal and cognitive deficits.4,7 CF individuals often have increased 
requirements during periods of pulmonary exacerbation; this 
increases oxidative stress.4 Studies that demonstrated that vitamin 
E supplementation increases serum vitamin E levels failed to show a 
direct clinical benefit.4,7 
A number of studies have shown that CF individuals often have 
suboptimal levels of vitamin K and those with CFLD are almost 
always deficient.4,7 Vitamin K plays an essential role in blood clotting 
and also contributes to bone health.4,7 The measurement of vitamin K 
is problematic in practice and tests are expensive and therefore not 
routinely used.4,7 The measurement of prothrombin time is insensitive 
and only elevated in a severe deficiency.4,7 Regular supplementation 
of dietary  vitamin K1 is recommended.
4 Currently there is insufficient 
data available to determine the appropriate dosage of vitamin K.4 




Vitamin A Beta-carotene 1 mg/kg/day for 12 
weeks (Maximum 50 mg/day). 
10 mg/day
Vitamin D 800 IU/day 2 000 IU
Vitamin E 100–400 IU
Vitamin K 1–10 mg/day
Probiotics 
The use of probiotics in improving health outcomes related to 
respiratory, gastrointestinal and nutrition in CF is a new topic that is 
being investigated.² 
Two randomised controlled trials (RCT) showed that probiotics 
resulted in a reduction in pulmonary exacerbations (PE).² Two pilot 
studies investigated the role of probiotics in reducing the duration 
and severity of PE but showed no clinical benefit.2 Two RCT 
investigated the effect of probiotics on the number and duration of 
hospital admissions for PE.² The results were inconclusive for the 
effect of probiotics on hospital admissions and showed no effect on 
duration of hospital stay.²
In terms of improvements in gastrointestinal and nutritional 
outcomes the results are either currently inconclusive or showed no 
significant functional improvement.2
Conclusion 
This patient presented with a combination of CF-related 
complications that were managed or improved through nutritional 
intervention. Following the current guidelines and recommendations 
as well as regular monitoring of nutrition-related complications 
dramatically improves the quality of life and prognosis of CF patients. 
The patient was discharged on post-transplant day 16 and received 
ONS for home use (500 kCal TE, 14 g protein per day). He is being 
followed up as an outpatient and has gained 4.5kg since discharge. 
He has also started exercising under physician supervision and is 
able to cycle 2 km. His nutritional regimen will be monitored and 
adjusted as his activity level increases to ensure adequate weight 
gain and maintenance. 
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